- Home
- VIVK vs PRLD Comparison
VIVK vs PRLD Comparison
Compare VIVK & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVK
- PRLD
- Stock Information
- Founded
- VIVK 2006
- PRLD 2016
- Country
- VIVK United States
- PRLD United States
- Employees
- VIVK N/A
- PRLD N/A
- Industry
- VIVK Oilfield Services/Equipment
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- VIVK Energy
- PRLD Health Care
- Exchange
- VIVK Nasdaq
- PRLD Nasdaq
- Market Cap
- VIVK 38.4M
- PRLD 44.0M
- IPO Year
- VIVK N/A
- PRLD 2020
- Fundamental
- Price
- VIVK $0.68
- PRLD $1.25
- Analyst Decision
- VIVK
- PRLD Strong Buy
- Analyst Count
- VIVK 0
- PRLD 3
- Target Price
- VIVK N/A
- PRLD $4.00
- AVG Volume (30 Days)
- VIVK 183.5K
- PRLD 219.0K
- Earning Date
- VIVK 08-19-2025
- PRLD 11-05-2025
- Dividend Yield
- VIVK N/A
- PRLD N/A
- EPS Growth
- VIVK N/A
- PRLD N/A
- EPS
- VIVK N/A
- PRLD N/A
- Revenue
- VIVK $124,048,464.00
- PRLD $7,000,000.00
- Revenue This Year
- VIVK N/A
- PRLD N/A
- Revenue Next Year
- VIVK N/A
- PRLD N/A
- P/E Ratio
- VIVK N/A
- PRLD N/A
- Revenue Growth
- VIVK 98.83
- PRLD N/A
- 52 Week Low
- VIVK $0.53
- PRLD $0.61
- 52 Week High
- VIVK $1.89
- PRLD $5.53
- Technical
- Relative Strength Index (RSI)
- VIVK 39.10
- PRLD 60.92
- Support Level
- VIVK $0.67
- PRLD $1.10
- Resistance Level
- VIVK $0.88
- PRLD $1.26
- Average True Range (ATR)
- VIVK 0.07
- PRLD 0.15
- MACD
- VIVK -0.01
- PRLD 0.00
- Stochastic Oscillator
- VIVK 4.99
- PRLD 81.13
About VIVK Vivakor Inc.
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.